Taken together, in the present study, we found that the absence of disappearance of arterial tumor enhancement on CE-CT, AFP ratio of >1.2, and two or more increments in the CP score after 2 weeks of sorafenib therapy were significant and independent predictors of worse survival and that these three worse prognostic factors were also associated with a significantly higher PD rate according to modified RECIST at 6 weeks after sorafenib therapy. Here, AFP is linked to neoplasm.